The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis.
Sakshi BamiAnshul VagrechaDanielle SobermanMohamad BadawiDaniel CannoneJeffrey M LiptonRandy Q CronCarolyn Fein LevyPublished in: Pediatric blood & cancer (2020)
Initial treatment with anakinra (with or without dexamethasone) is a feasible treatment alternative for patients with secondary HLH and may allow for avoidance of etoposide. We recommend early initiation of anakinra when HLH is suspected. A broader investigation of the use of anakinra as a first-line agent for HLH is ongoing.
Keyphrases